Exhibit 99.1

DANAHER REPORTS FOURTH QUARTER AND FULL YEAR 2009 RESULTS

WASHINGTON, D.C., January 28, 2010 — Danaher Corporation (NYSE:DHR) announced today that GAAP net earnings for the quarter ended December 31, 2009 were $267 million, or $0.80 per diluted share, a 13% decrease as compared to the Company’s 2008 fourth quarter GAAP net earnings of $306 million, or $0.92 per diluted share. On a non-GAAP basis, which reflects the adjustments identified in the attached reconciliation schedule, adjusted net earnings for the quarter ended December 31, 2009 were $375 million or $1.12 per diluted share, a 1% increase over 2008 fourth quarter adjusted net earnings of $371 million or $1.11 per diluted share. Sales for the 2009 fourth quarter were $3.1 billion, 1.5% less than the $3.2 billion reported for the 2008 fourth quarter. Core revenues declined 9% in the quarter, compared to the fourth quarter of 2008.

GAAP net earnings for the full year 2009 were $1.15 billion, or $3.46 per diluted share, compared with GAAP net earnings of $1.32 billion, or $3.95 per diluted share for 2008. Sales for the full year 2009 were $11.2 billion compared to $12.7 billion for the full year 2008, a decrease of 12%.

H. Lawrence Culp, Jr., President and Chief Executive Officer, stated, “We were encouraged by the continued sequential end market improvements in the fourth quarter, as well as our team’s solid execution on the restructuring initiatives undertaken throughout the year. Our continued focus on internal growth investments, new product introductions and strategic M&A opportunities give us confidence that we can outperform in 2010 and over the long term.”

Danaher will discuss its results during its investor conference call today starting at 7:30 a.m. EST. The call and an accompanying slide presentation will be webcast on the “Investors” section of Danaher’s website at www.danaher.com. A replay of the webcast can be accessed on the “Investors” section of Danaher’s website (under the subheading “Investor Events”) shortly after the conclusion of the presentation, and the webcast will remain available until the next quarterly earnings call. The conference call can be accessed by dialing 888-417-2254 in the US or 719-325-2339 outside the US a few minutes before the 7:30 a.m. EST start and telling the operator that you are dialing in for Danaher’s investor conference call, access code 5742258. A replay of the conference call will be available shortly after the conclusion of the call until February 2, 2010 and you can access the replay by dialing 888-203-1112 in the US or 719-457-0820 outside the US, access code 5742258. In addition, presentation materials relating to Danaher’s results have been posted to the “Investors” section of Danaher’s website under the subheading “Earnings.”

* * *

Danaher is a diversified technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. Our portfolio of premier brands is among the most highly recognized in each of the markets we serve. Driven by a foundation provided by the Danaher Business System, our 47,000 associates serve customers in more than 125 countries and generated $11.2 billion of revenue in 2009. For more information please visit our website: www.danaher.com.

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons why we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures and other information relating to these measures are included in the supplemental reconciliation schedule attached.

Statements in this release that are not strictly historical, including the statements regarding execution of cost reduction activities, growth investments, new product introductions, acquisitions and expectations for 2010 and future periods and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be “forward-looking” statements. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the current uncertainty in the global economy and credit markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully

1

market new products and technologies and expand into new markets, our ability to successfully identify, consummate and integrate appropriate acquisitions, contingent liabilities relating to acquisitions, risks relating to potential impairment of goodwill and other long-lived assets, currency exchange rates, our compliance with applicable laws and regulations and changes in applicable laws and regulations, tax audits and changes in our tax rate, litigation and other contingent liabilities including intellectual property and environmental matters, risks relating to product defects and recalls, the impact of our debt obligations on our operations, pension plan costs, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, legislative health care reform and other changes in health care industry, labor matters, our relationships with and the performance of our channel partners, risks relating to man-made and natural disasters, our ability to achieve projected cost reductions and growth, and international economic, political, legal and business factors. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2008 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended October 2, 2009. These forward-looking statements speak only as of the date of this release and the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

To download a copy of the full earnings report, please go to www.danaher.com.

Please contact:

Matt R. McGrew
Vice President, Investor Relations Danaher Corporation 2099 Pennsylvania Avenue Washington, D.C. 20006
Telephone:	(202) 828-0850
Fax:	(202) 828-0860

2

DANAHER CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS

($ in thousands, except per share amounts)

	Three Months Ended						Year Ended
	12/31/09			12/31/08			12/31/09			12/31/08
Sales	$	3,132,892		$	3,176,506		$	11,184,938		$	12,697,456
Operating costs and expenses:
Cost of sales		1,694,507			1,724,897			5,904,718			6,757,262
Selling, general and administrative expenses		890,455			860,491			3,190,211			3,345,274
Research and development expenses		154,216			167,467			632,651			725,443
Other (income) expense		—			—			(85,118	)		—
Total operating expenses		2,739,178			2,752,855			9,642,462			10,827,979
Operating profit		393,714			423,651			1,542,476			1,869,477
Interest expense		(35,428	)		(25,433	)		(122,656	)		(130,174	)
Interest income		1,649			4,000			5,034			10,004
Earnings before income taxes		359,935			402,218			1,424,854			1,749,307
Income taxes		(93,000	)		(96,532	)		(273,150	)		(431,676	)
Net earnings	$	266,935		$	305,686		$	1,151,704		$	1,317,631
Net earnings per share:
Basic	$	0.83		$	0.96		$	3.59		$	4.13
Diluted	$	0.80		$	0.92		$	3.46		$	3.95
Average common stock and common equivalent shares outstanding:
Basic		322,716			319,523			320,765			319,361
Diluted		338,680			333,593			335,742			335,863

This information is presented for reference only. Final audited financial statements will include footnotes, which should be referenced when available, to more fully understand the contents of this information.

3

DANAHER CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

As of December 31 ($ and shares in thousands)

	2009		2008
ASSETS
Current Assets:
Cash and equivalents	$	1,721,920	$	392,854
Trade accounts receivable, less allowance for doubtful accounts of $133,103 and $120,730, respectively		1,916,831		1,894,585
Inventories		993,016		1,142,309
Prepaid expenses and other current assets		588,861		757,371
Total current assets		5,220,628		4,187,119
Property, plant and equipment, net		1,143,331		1,108,653
Other assets		758,035		464,353
Goodwill		9,817,923		9,210,581
Other intangible assets, net		2,655,503		2,519,422
Total assets	$	19,595,420	$	17,490,128
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Notes payable and current portion of long-term debt	$	44,186	$	66,159
Trade accounts payable		1,051,487		1,108,961
Accrued expenses and other liabilities		1,665,287		1,569,977
Total current liabilities		2,760,960		2,745,097
Other long-term liabilities		2,315,261		2,383,299
Long-term debt		2,889,023		2,553,170
Stockholders’ equity:
Common stock - $0.01 par value, 1 billion shares authorized; 358,922 and 354,487 issued; 322,735 and 318,380 outstanding, respectively		3,589		3,544
Additional paid-in capital		2,074,501		1,812,963
Retained earnings		9,205,142		8,095,155
Accumulated other comprehensive income (loss)		346,944		(103,100	)
Total stockholders’ equity		11,630,176		9,808,562
Total liabilities and stockholders’ equity	$	19,595,420	$	17,490,128

This information is presented for reference only. Final audited financial statements will include footnotes, which should be referenced when available, to more fully understand the contents of this information.

4

DANAHER CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

Year Ended December 31 ($ in thousands)

	2009			2008
Cash flows from operating activities:
Net earnings	$	1,151,704		$	1,317,631
Non-cash items:
Depreciation		184,524			193,997
Amortization		157,063			145,290
Stock compensation expense		87,350			86,000
Consideration received in shares		(84,749	)		—
Change in deferred income taxes		(120,031	)		27,691
Change in trade accounts receivable, net		106,132			71,403
Change in inventories		211,595			33,119
Change in accounts payable		(89,853	)		3,713
Change in prepaid expenses and other assets		142,396			(4,773	)
Change in accrued expenses and other liabilities		54,703			(15,042	)
Total operating cash flows		1,800,834			1,859,029
Cash flows from investing activities:
Payments for additions to property, plant and equipment		(188,547	)		(193,783	)
Proceeds from disposals of property, plant and equipment		6,090			1,088
Cash paid for acquisitions		(703,511	)		(423,208	)
Cash paid for other investments		(66,768	)		—
Proceeds from divestitures, sale of investment and refundable escrowed purchase price		9,795			48,504
Total investing cash flows		(942,941	)		(567,399	)
Cash flows from financing activities:
Proceeds from issuance of common stock		174,233			82,430
Payment of dividends		(41,717	)		(38,259	)
Purchase of treasury stock		—			(74,165	)
Net repayments of borrowings (maturities of 90 days or less)		(445,711	)		(905,567	)
Proceeds of borrowings (maturities longer than 90 days)		744,615			72,652
Repayments of borrowings (maturities longer than 90 days)		(24,188	)		(259,344	)
Net cash (used in) provided by financing activities		407,232			(1,122,253	)
Effect of exchange rate changes on cash and equivalents		63,941			(15,631	)
Net change in cash and equivalents		1,329,066			153,746
Beginning balance of cash and equivalents		392,854			239,108
Ending balance of cash and equivalents	$	1,721,920		$	392,854

This information is presented for reference only. Final audited financial statements will include footnotes, which should be referenced when available, to more fully understand the contents of this information.

5

DANAHER CORPORATION AND SUBSIDIARIES

SEGMENT INFORMATION

($ in thousands, unaudited)

	Three Months Ended						Year Ended
	12/31/09			12/31/08			12/31/09			12/31/08
Sales
Professional Instrumentation	$	1,224,686		$	1,243,949		$	4,330,695		$	4,860,764
Medical Technologies		921,050			843,820			3,141,916			3,277,026
Industrial Technologies		705,116			777,932			2,658,041			3,265,451
Tools & Components		282,040			310,805			1,054,286			1,294,215
	$	3,132,892		$	3,176,506		$	11,184,938		$	12,697,456
Operating Profit
Professional Instrumentation	$	228,171		$	221,960		$	728,479		$	907,254
Medical Technologies		78,043			90,134			395,489			370,473
Industrial Technologies		80,926			106,569			383,241			522,112
Tools & Components		29,520			30,343			124,814			157,673
Other		(22,946	)		(25,355	)		(89,547	)		(88,035	)
	$	393,714		$	423,651		$	1,542,476		$	1,869,477
Operating Margins
Professional Instrumentation		18.6	%		17.8	%		16.8	%		18.7	%
Medical Technologies		8.5	%		10.7	%		12.6	%		11.3	%
Industrial Technologies		11.5	%		13.7	%		14.4	%		16.0	%
Tools & Components		10.5	%		9.8	%		11.8	%		12.2	%
Total		12.6	%		13.3	%		13.8	%		14.7	%
Restructuring & Other Related Charges
Professional Instrumentation	$	40,184		$	28,813		$	99,016		$	28,813
Medical Technologies		44,847			26,081			60,531			26,081
Industrial Technologies		40,858			23,093			60,701			23,093
Tools & Components		11,243			3,978			18,281			3,978
Total	$	137,132		$	81,965		$	238,529		$	81,965
Restructuring Cost Classification
Cost of sales	$	87,303		$	33,130		$	121,783		$	33,130
Selling, general and administrative expenses		49,829			48,835			116,746			48,835
	$	137,132		$	81,965		$	238,529		$	81,965

This information is presented for reference only. Final audited financial statements will include footnotes, which should be referenced when available, to more fully understand the contents of this information

6

DANAHER CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

($ in 000’s except per share data)

	Three Months Ended							Year Ended
	December 31, 2009		December 31, 2008			% Change		December 31, 2009			December 31, 2008			% Change
Adjusted Net Earnings
Net Earnings (GAAP)	$	266,935	$	305,686		-12.7	%	$	1,151,704		$	1,317,631		-12.6	%
Restructuring charges in excess of amounts originally budgeted for the applicable period ($125 million and $82 million pre-tax for the three months ended December 31, 2009 and 2008, respectively, and $190 million and $82 million pre-tax for the years ended December 31, 2009 and 2008, respectively) (“Additional Restructurings”)		93,750		61,500					144,365			61,500
2009 transaction costs associated with completed and pending acquisitions (expensed in accordance with the adoption of the new business combination accounting standard) ($12 million and $24 million pre-tax for the three months and year ended December 31, 2009, respectively), and fair value adjustments to acquisition-related inventory and deferred revenue balances incurred in 2009 ($3 million and $13 million pre-tax for the three months and year ended December 31, 2009, respectively) and in 2008 ($7 million and $52 million pre-tax for the three months and year ended December 31, 2008, respectively) (“Acquisition Related Costs”)		14,250		5,150					31,767			44,465
Gain on intellectual property litigation settlement with Align Technology, Inc. ($85 million pre-tax). (“Align Settlement Gain”)		—		—					(53,412	)		—
Gains from net reduction in income tax reserves and discrete tax benefits (“Discrete Income Tax Items”)		—		(1,160	)				(97,229	)		(9,524	)
Adjusted Net Earnings (Non-GAAP)	$	374,935	$	371,176		1.0	%	$	1,177,195		$	1,414,072		-16.8	%
Adjusted Diluted Net Earnings Per Share
Diluted Net Earnings Per Share (GAAP)	$	0.80	$	0.92		-13.0	%	$	3.46		$	3.95		-12.4	%
Additional Restructurings		0.28		0.18					0.43			0.18
Acquisition Related Costs		0.04		0.01					0.09			0.13
Align Settlement Gain		—		—					(0.16	)		—
Discrete Income Tax Items		—		—					(0.29	)		(0.03	)
Adjusted Diluted Net Earnings Per Share (Non-GAAP)	$	1.12	$	1.11		0.9	%	$	3.53		$	4.23		-16.5	%

7

Core Revenue Growth/Decline

Components of Sales Growth	Three Months Ended December 31, 2009 vs. Comparable 2008 Period		Year Ended December 31, 2009 vs. Comparable 2008 Period
Core (non-GAAP)	-9.0	%	-12.0	%
Acquisitions (non-GAAP)	3.0	%	2.0	%
Impact of currency translation (non-GAAP)	4.5	%	-2.0	%
Total Sales Growth/Decline (GAAP)	-1.5	%	-12.0	%

General

We believe that the non-GAAP measures set forth in this presentation, when viewed with and reconciled to the corresponding GAAP measures, provide additional understanding of Danaher’s performance and help identify underlying trends in Danaher’s business. The non-GAAP measures should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measures.

Adjusted Net Earnings and Adjusted Diluted Net Earnings Per Share

We use the term adjusted net earnings and adjusted diluted net earnings per share to refer to GAAP net earnings and GAAP diluted net earnings per share, respectively, excluding the items identified in the reconciliation schedule above. These items have been excluded from the non-GAAP measures because items of this nature and/or size occur with inconsistent frequency, for reasons that may be unrelated to Danaher’s commercial performance during the period and/or we believe are not indicative of Danaher’s ongoing operating costs or gains in a given period. We believe that these measures reflect additional ways of viewing aspects of Danaher’s operations that, when viewed with and reconciled to the corresponding GAAP measures, help our investors to better understand the long-term profitability trends of our business, and facilitate easier comparisons of our profitability to prior and future periods and to our peers. We believe that investors use these measures to (1) generally assess the performance of our operating model, including assessing Danaher’s performance against prior period performance, forecasted performance and/or peer company performance, (2) forecast financial results for future periods, (3) identify trends in Danaher’s performance, and (4) value Danaher.

The Company estimates the tax effect of the items identified in the reconciliation schedule above by applying the Company’s overall estimated effective tax rate to the pre-tax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.

Core Revenue and Core Revenue Growth/Decline

We use the term “core revenue” to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition (“acquisition sales”), and (2) the impact of currency translation. The portion of GAAP revenue attributable to currency translation is calculated as the difference between (a) the period-to-period change in GAAP revenue (excluding acquisition sales) and (b) the period-to-period change in revenue (excluding acquisition sales) after applying current period foreign exchange rates to the prior year period. We use the term “core revenue growth/decline” to refer to the measure of comparing current period core revenue with the corresponding period of the prior year. We exclude the effect of currency translation from these measures because currency translation is not under management’s control, is subject to volatility and can therefore obscure underlying business trends. We exclude the effect of acquisitions because the nature, size and number of acquisitions can vary dramatically from period to period and between us and our peers, which we believe may obscure underlying business trends and makes comparisons of long-term performance difficult. We believe that these measures reflect additional ways of viewing aspects of Danaher’s operations that, when viewed with and reconciled to the corresponding GAAP measures, help our investors to better identify and understand underlying growth trends in our business, and facilitate easier comparisons of our results of operations with prior and future periods and to our peers. We believe that investors use these measures to help gauge Danaher’s long-term growth prospects and to value Danaher.

8